CARB-X announced today that it’s awarding Chembio Diagnostic Systems $1.8 million to support the development of a rapid, finger stick–based diagnostic test for typhoid fever.
The money will help Chembio, of Medford, New York, develop a blood-based point-of-care test, using its proprietary Dual Path Platform, that can detect acute infection caused by Salmonella enterica serovar Typhi based on the presence of immunoglobulin A (IgA) antibodies. Chembio says using IgA antibody detection will provide more accurate results than current rapid tests for typhoid fever, ensure timely treatment, and minimize selective pressure for antibiotic resistance.
Typically spread through consumption of contaminated food or water, typhoid fever causes an estimated 11 million to 21 million illnesses a year, primarily in countries in South Asia, Southeast Asia, and sub-Saharan Africa. The primary symptoms are abdominal pain and a high, prolonged fever.
Could be good news for lower-income nations
“A rapid, fingerstick-based test that delivers reliable results at the point of care could significantly improve how typhoid fever is diagnosed in low- and middle-income countries, where access to laboratory infrastructure is often limited,” Richard Alm, PhD, interim chief of research & development at CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), said in a press release. “If successful, Chembio’s diagnostic capability can support better clinical decision-making, strengthen surveillance and stewardship efforts, and contribute to more effective management of enteric fever in high-burden settings.”
Since its founding in 2016, CARB-X has funded 122 projects designed to prevent, treat, and diagnose antibiotic-resistant infections.